Introduction The ideal management of patients with unresectable non-small-cell lung cancer
(NSCLC) is still developing. Unresectable NSCLC has a high mortality rate and poor …

Abstract Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when
the disease has progressed to clinical stage III. At this stage, and even if the cancer is …

Chemotherapy remains a cornerstone in the treatment of nonsm... : Current Opinion in
Oncology Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer …

In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued
to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former …

Advanced non‐small cell lung cancer (NSCLC) is a complex disease comprising
molecularly distinct tumor types, each with a unique biology that is becoming increasingly …

Research on biomarker-driven therapy and immune check-point blockade in non-small cell
lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also …

In 2018 research in the field of advanced NSCLCs led to an expanded reach and impact of
immune checkpoint inhibitors (ICIs) as part of a frontline treatment strategy, regardless of …

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape of advanced
non-small-cell lung cancer (NSCLC). It has improved the overall survival in the first-and …

Opinion statement Targeted therapies and more recently immune checkpoint inhibitors (ICI)
have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating …

Lung cancer is the leading cause of cancer death in the United States and many other parts
of the world. Non–small cell lung cancer (NSCLC) comprises 85–90% of lung cancers …